BridgeBio Pharma Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 975.31, 1636.94, 2404, 3348.15, 4261.98 ], "ebit_estimate": [ -295.44, 205.52, 823.27, 1581.91, 2337.11 ], "ebitda_estimate": [ -308.27, 193.9, 533.51, 516, 988 ], "net_income_estimate": [ -437.9, 136.59, 827.96, 1518.45, 2186.5 ], "per_share_eps_estimate": [ -2.03, 0.61, 3.79, 6.66, 9.41 ], "eps_nri_estimate": [ -2.18, 0.57, 3.85, 7, 9.41 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ -12.37, -8.62, -1.31, null, null ], "pretax_income_estimate": [ -423.81, 140.36, 866.9, 1600.81, 2359.45 ], "operating_cash_flow_per_share_estimate": [ -1.95, 1.76, null, null, null ], "roa_estimate": [ -34.3, 8.65, -10, 10.2, 18.3 ], "roe_estimate": [ 25.85, -0.75, 30, -35.9, -346.6 ], "gross_margin_estimate": [ 93.01, 91.91, 91.25, 91.5, 91.75 ], "operating_cash_flow_estimate": [ -379.84, 342.83, null, null, null ], "pettm_estimate": [ 0, 140.9, 22.67, 12.88, 9.12 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "68.48", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 68.48, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": 48.65, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 223.71, 248.34, 287.34, 299.46, 351.62, 409.07, 467.2, 525.44 ], "ebit_estimate": [ -82.89, -67.31, -41.33, -38.04, -4.32, 42.46, 90.2, null ], "ebitda_estimate": [ -79.14, -58.91, -37.77, -52.43, -16.38, null, null, null ], "net_income_estimate": [ -109.76, -93.25, -75.78, -51.92, -34.18, 20.78, 53.7, null ], "per_share_eps_estimate": [ -0.55, -0.47, -0.28, -0.22, -0.06, 0.18, 0.4, null ], "eps_nri_estimate": [ -0.56, -0.47, -0.32, -0.25, -0.07, 0.16, 0.37, 0.43 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -117.97, -95.75, -78.04, -55.4, -34.18, 18.6, 48, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 91.67, 92.33, 92.67, 96, 96, 96, 95.5, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 280.42, null, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "68.48", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 68.48, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": 48.65, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }